AB Science Secures €2.3M Private Placement to Fund Key R&D Programs
Event summary
- AB Science completed a €2.3 million private placement on July 1, 2026.
- Proceeds will fund R&D for AB8939 (acute myeloid leukemia) and masitinib (amyotrophic lateral sclerosis).
- The deal issued 3.47 million new shares with attached share warrants at a 24.56% discount to the 3-day VWAP.
- New shares are expected to begin trading on Euronext Paris on July 6, 2026.
The big picture
AB Science's €2.3 million private placement underscores the biotech sector's reliance on targeted funding to advance high-risk, high-reward therapies. The strategic focus on acute myeloid leukemia and amyotrophic lateral sclerosis reflects broader industry trends toward precision medicine and orphan drug development. With a 24.56% discount to recent share prices, the deal highlights investor appetite for growth-stage biotech despite market volatility.
What we're watching
- Execution Risk
- Whether AB Science can deliver on its R&D milestones with the new funding.
- Market Reaction
- How the market will respond to the dilution and the strategic focus on key programs.
- Investor Dynamics
- The pace at which existing shareholders may adjust their positions post-placement.
Related topics